Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Бусад хувилбаруудыг харуулах (1)

Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells in the bone marrow and the development of osteolytic bone disease. The present study demonstrates that myeloma cells express the critical osteoclastogenic factor RANKL (the ligand for receptor activator of NF-k...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Croucher, P, Shipman, C, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, A, van Beek, E, Holen, I, Skerry, T, Dunstan, C, Russell, G, Van Camp, B, Vanderkerken, K
Формат:	Journal article
Хэл сонгох:	English
Хэвлэсэн:	2001

Ижил төстэй зүйлс

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
-н: Croucher, P, зэрэг
Хэвлэсэн: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
-н: Croucher, P, зэрэг
Хэвлэсэн: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
-н: Croucher, P, зэрэг
Хэвлэсэн: (2001)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
-н: Croucher, P, зэрэг
Хэвлэсэн: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
-н: Croucher, P, зэрэг
Хэвлэсэн: (2002)

Osteoprotegerin and the development of myeloma bone disease
-н: Croucher, P, зэрэг
Хэвлэсэн: (2004)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
-н: Shipman, C, зэрэг
Хэвлэсэн: (2000)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
-н: Vanderkerken, K, зэрэг
Хэвлэсэн: (2003)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
-н: Shipman, C, зэрэг
Хэвлэсэн: (2002)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
-н: Shipman, C, зэрэг
Хэвлэсэн: (2000)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
-н: De Leenheer, E, зэрэг
Хэвлэсэн: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
-н: Shipman, C, зэрэг
Хэвлэсэн: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
-н: Croucher, P, зэрэг
Хэвлэсэн: (2003)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
-н: Croucher, P, зэрэг
Хэвлэсэн: (2002)

Role of osteoprotegerin (OPG) in cancer.
-н: Holen, I, зэрэг
Хэвлэсэн: (2006)

Bisphosphonates--mechanisms of action in multiple myeloma.
-н: Shipman, C, зэрэг
Хэвлэсэн: (2000)

Bisphosphonates and in vivo models of multiple myeloma - Reply
-н: Shipman, C, зэрэг
Хэвлэсэн: (2001)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
-н: Shipman, C, зэрэг
Хэвлэсэн: (2000)

The role of osteoprotegerin in breast and prostate cancer
-н: Holen, I, зэрэг
Хэвлэсэн: (2002)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
-н: De Leenheer, E, зэрэг
Хэвлэсэн: (2002)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
-н: Shipman, C, зэрэг
Хэвлэсэн: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
-н: Shipman, C, зэрэг
Хэвлэсэн: (2003)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
-н: Holen, I, зэрэг
Хэвлэсэн: (2002)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
-н: Eaton, C, зэрэг
Хэвлэсэн: (2004)

RANKL/RANK/osteoprotegerin system as novel therapeutic target in the treatment of primary bone tumors and osteolytic metastases
-н: Anđelković Zlatibor, зэрэг
Хэвлэсэн: (2004-01-01)

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
-н: Huan Liu, зэрэг
Хэвлэсэн: (2022-06-01)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
-н: Mueller, G, зэрэг
Хэвлэсэн: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
-н: Mueller, G, зэрэг
Хэвлэсэн: (2004)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
-н: Edwards, C, зэрэг
Хэвлэсэн: (2007)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
-н: Holen, I, зэрэг
Хэвлэсэн: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
-н: Eaton, C, зэрэг
Хэвлэсэн: (2004)

Osteolytic lesions: Multiple myeloma or prostate cancer?
-н: Akshitha Devaraj, MBBS, зэрэг
Хэвлэсэн: (2023-04-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
-н: Aiken Dao, зэрэг
Хэвлэсэн: (2022-12-01)

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
-н: Dongyeop Shin, зэрэг
Хэвлэсэн: (2024-01-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
-н: Locklin, R, зэрэг
Хэвлэсэн: (2005)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
-н: Waterman, E, зэрэг
Хэвлэсэн: (2007)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
-н: Dongzheng Gai, зэрэг
Хэвлэсэн: (2022-09-01)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
-н: Domingos Sousa, зэрэг
Хэвлэсэн: (2020-11-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
-н: Dirk Hose, зэрэг
Хэвлэсэн: (2024-12-01)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
-н: Lwin, S, зэрэг
Хэвлэсэн: (2017)